Sign in
Taking people in United StatesNo phase

Checking spine tissue from older adults for a heart protein buildup

Checks spinal tissue from adults 50 and older for signs of heart amyloidosis.

Key facts

Who runs it
Columbia University
Where
Beverly Hills, Boston, Cleveland, New York, and Rochester, United StatesSee the 6 sites
Trial code
Registry title
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Status
Recruiting
People taking part
1,663 people, planned
Started
19 Sept 2023
Expected to end
May 2028
Type of study
Observational, 2 groups
Treatments tested
  • Tc99-PYP or Tc99-HDMP Scan
Record updated
4 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 50 or older who had spine surgery for lumbar spinal stenosis in the last 20 years. Their spine tissue will be checked for amyloid, a protein build-up that can affect the heart.

Age
50 years or older at the time of the surgery.
Sex
All sexes can join.
Disease stage
A person who had spinal decompression surgery that was clinically needed, within 20 years before joining.
Earlier treatment
Must have had spinal decompressive surgery within 20 years before enrollment.

Main reasons for not taking part

  • Confirmed primary amyloidosis (AL) or secondary amyloidosis (AA)
  • Known TTR amyloidosis
  • Another reason that makes the person inappropriate for the study

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Clinically indicated spinal decompressive surgery within 20 years prior to enrollment
  • Age ≥50 years at the time of the surgery
  • Able to understand and sign the informed consent document after the nature of the study has been fully explained

Who cannot take part

  • The presence of any of the following excludes eligibility for enrollment in this study:
  • Confirmed primary amyloidosis (AL) or secondary amyloidosis (AA)
  • Known TTR amyloidosis
  • Other reason that would make the subject inappropriate for entry into this study

Where in United States

  • Cedars-Sinai Medical CenterBeverly Hills, United StatesContact: Shruti ShantharamTaking people
  • Boston Medical CenterBoston, United StatesContact: Frederick Ruberg, MDTaking people
  • Tufts Medical CenterBoston, United StatesContact: Ayan Patel, MDTaking people
  • Cleveland ClinicCleveland, United StatesContact: Mazen Hanna, MDTaking people
  • Columbia University Irving Medical CenterNew York, United StatesContact: Jeffeny DeLosSantos, MHATaking people
  • Mayo ClinicRochester, United StatesContact: Mathew S Maurer, MDNo longer taking part

About the trial

What the trial wants to find out

Primary objective:

Read full original descriptionShow less

To identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course of the illness, at a time when disease modifying therapies are most effective.

The specific aims of this epidemiologic investigation include:

1. To identify subjects with previous lumbar spinal stenosis (LSS) Surgery who have evidence of transthyretin (TTR) amyloid deposits in spinal specimens and could be at risk for ATTR cardiac amyloidosis. 2. To evaluate for ATTR-CA among those with localized TTR in the spinal tissue.

The study will also explore the following:

1. The prevalence of amyloid in lumbar spinal stenosis specimens by Congo Red staining. 2. The prevalence of TTR deposits among subjects with amyloid as determined by mass spectrometry. 3. Evaluation of a novel artificial intelligence technique for that can identify amyloid histologically with standard H\&E staining. 4. Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in subject's spine by myocardial uptake of technetium pyrophosphate scan (Tc99-PYP).

The 2 groups in the trial

  • ATTR Negative

    Participants who have undergone previous lumbar spinal, and/or carpel tunnel surgery will provide medical record data and spinal specimen for analysis of presence of ATTR amyloid.

  • ATTR Positive

    Participants who have undergone previous lumbar spinal, and/or carpel tunnel surgery will provide medical record data, spinal specimen, prospective data from cardiac workup with confirmed ATTR amyloid in spinal specimen then undergo cardiac workup for cardiac phenotyping/genotyping.

    Treatment: Tc99-PYP or Tc99-HDMP Scan

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Plain-language title
Checking spine tissue from older adults for a heart protein buildupGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 June 2026